Busti Anthony J, Hooper Justin S, Amaya Christopher J, Kazi Salahuddin
Texas Tech University Health Sciences Center School of Pharmacy, Dallas-Ft. Worth Regional Campus, Dallas, Texas 75216, USA.
Pharmacotherapy. 2005 Nov;25(11):1566-91. doi: 10.1592/phco.2005.25.11.1566.
Patients with various rheumatologic and inflammatory disease states commonly require drugs known to decrease the inflammatory or autoimmune response for adequate control of their condition. Such drugs include nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 inhibitors, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers. These drugs affect inflammation and local immune responses, which are necessary for proper wound healing in the perioperative setting, thereby potentially resulting in undesirable postoperative complications. Such complications include wound dehiscence, infection, and impaired collagen synthesis. The end result is delayed healing of soft tissue and bone wounds. The current literature provides insight into the effect of some of these drugs on wound healing. For certain drugs, such as methotrexate, trials have been conducted in humans and direct us on what to do during the perioperative period. Whereas with other drugs, we must rely on either small-animal studies or extrapolation of data from human studies that did not specifically look at wound healing. Unfortunately, no clear consensus exists on the need and optimum time for withholding therapy before surgery. Likewise, clinicians are often uncertain of the appropriate time to resume therapy after the procedure. For those drugs with limited or no data in this setting, the use of pharmacokinetic properties and biologic effects of each drug should be considered individually. In some cases, discontinuation of therapy may be required up to 4 weeks before surgery because of the long half-lives of the drugs. In doing so, patients may experience an exacerbation or worsening of disease. Clinicians must carefully evaluate individual patient risk factors, disease severity, and the pharmacokinetics of available therapies when weighing the risks and benefits of discontinuing therapy in the perioperative setting.
患有各种风湿性和炎性疾病状态的患者通常需要使用已知可降低炎症或自身免疫反应的药物,以充分控制病情。这类药物包括非甾体抗炎药(NSAIDs)、环氧化酶(COX)-2抑制剂、皮质类固醇、改善病情抗风湿药(DMARDs)和生物反应调节剂。这些药物会影响炎症和局部免疫反应,而这对于围手术期伤口的正常愈合是必需的,从而可能导致不良的术后并发症。此类并发症包括伤口裂开、感染和胶原合成受损。最终结果是软组织和骨伤口愈合延迟。当前的文献为其中一些药物对伤口愈合的影响提供了见解。对于某些药物,如甲氨蝶呤,已在人体进行了试验,并指导我们在围手术期该怎么做。而对于其他药物,我们必须依赖小动物研究或未专门观察伤口愈合情况的人体研究数据的外推。不幸的是,对于术前停药的必要性和最佳时间尚无明确共识。同样,临床医生通常也不确定术后恢复治疗的合适时间。对于在这种情况下数据有限或没有数据的那些药物,应分别考虑每种药物的药代动力学特性和生物学效应。在某些情况下,由于药物的半衰期较长,可能需要在手术前4周停药。这样做可能会使患者病情加重或恶化。临床医生在权衡围手术期停药的风险和益处时,必须仔细评估个体患者的风险因素、疾病严重程度以及现有治疗方法的药代动力学。